Direct-acting oral anticoagulants (DOACs) for VTE prophylaxis and treatment in patients with obesity

For VTE prophylaxis or treatment in patients with obesity, standard doses of apixaban or rivaroxaban are appropriate options regardless of BMI and weight; data are lacking on the use of dabigatranMartin, 2021. Observational studies are ongoing but at the time of writing, small numbers of patients above 150 kg have been included. Drug plasma concentration monitoring is not recommended because data are insufficient to influence management decisions.

For more information on VTE prophylaxis and treatment, including standard dosages, see Direct-acting oral anticoagulants for VTE prophylaxis and Direct-acting oral anticoagulants for VTE treatment.